[1]滕祥云,王新梦,刘　维,等.中国汉族结直肠癌患者 UGT1A1*28基因多态性分析[J].现代检验医学杂志,2019,34(06):20-23.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
　TENG Xiang-yun,WANG Xin-meng,LIU Wei,et al.Polymorphism of UGT1A1*28 Gene in Han Patients with Colorectal Cancer in China[J].Journal of Modern Laboratory Medicine,2019,34(06):20-23.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
点击复制

中国汉族结直肠癌患者 UGT1A1*28基因多态性分析 ()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
20-23
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Polymorphism of UGT1A1*28 Gene in Han Patients with Colorectal Cancer in China
文章编号:
1671-7414（2019）06-020-04
作者:
滕祥云; 王新梦; 刘　维; 樊　慧; 李　琦
( 长沙三济生物科技有限公司, 长沙　410205)
Author(s):
TENG Xiang-yun;  WANG Xin-meng;  LIU Wei; FAN Hui; LI Qi
（Changsha Sanji Biotechnology Co. Ltd., Changsha 410205, China）
关键词:
结直肠癌; 尿苷二磷酸葡醛酸转移酶; 基因多态性
分类号:
R735.3；R730.43
DOI:
10.3969 ／ j.issn.1671-7414.2019.06.005
文献标志码:
A
摘要:
目的　研究汉族人群中结直肠癌(colorectal cancer) 患者尿苷二磷酸葡醛酸转移酶1A1(UGT1A1)*28 基因多 态性的分布情况。方法　收集2016~2017 年合作医疗机构505 例汉族结直肠癌患者血液标本，通过焦磷酸测序技术检 测UGT1A1*28 基因型。根据性别、年龄和地区因素对患者进行分组，统计分析各组间结直肠癌患者UGT1A1*28 基 因型及等位基因分布情况。结果　在505 例结直肠癌患者中，UGT1A1*28 三种基因型TA6/TA6，TA6/TA7 和TA7/ TA7 频率分别为74.26%，22.97% 和2.77%。根据性别分组，患者UGT1A1*28 的3 种基因型在不同性别结直肠癌患者 中的分布差异无统计学意义(χ2=3.276，P > 0.05)。根据年龄分为≤ 44 岁，45~59 岁，60~74 岁和75~89 岁四组，患者 UGT1A1*28 的3 种基因型在不同年龄结直肠癌患者中的分布差异无统计学意义(P > 0.05)。根据地区分为山东、辽宁、 江苏、上海和甘肃五组，患者UGT1A1*28 的3 种基因型在不同地区结直肠癌患者中的分布差异无统计学意义(P > 0.05)。 结论　中国汉族结直肠癌患者UGT1A1*28 基因多态性主要为TA6/TA6 和UGT1A1*28 的3 种基因型分布与中国汉族结 直肠癌患者性别、年龄分层和地区差异无关。
Abstract:
Objective　To investigate the distribution of UGT1A1*28 gene polymorphism in patients with colorectal cancer in Han population. Methods　Blood samples from 505 Han patients with colorectal cancer from 2016 to 2017 in cooperative medical institutions were collected, the UGT1A1*28 genotype was detected by pyrosequencing, and the groups were divided according to gender, age and regional factors. The distribution of UGT1A1*28 genotypes and alleles in colorectal cancer patients were statistically analyzed. Results　In 505 cases of colorectal cancer, the TA6/TA6, TA6/TA7 and TA7/TA7 frequencies of UGT1A1*28 were 74.26%, 22.97% and 2.77%, respectively. There was no statistically significant in the distribution of UGT1A1*28 genotypes among patients of different genders with colorectal cancer (χ2=3.276，P > 0.05). According to age grouping ≤ 44 y，45~59 y，60~74 y and 75~89 y, the distribution of UGT1A1*28 genotypes in patients of different ages with colorectal cancer was no statistically significant (P > 0.05). According to the regional grouping of Shandong, Liaoning, Jiangsu, Shanghai and Gansu, the distribution of UGT1A1*28 genotypes in patients of different regions with colorectal cancer was no statistically significant （P > 0.05）. Conclusion 　The UGT1A1*28 gene polymorphism in Chinese Han colorectal cancer patients was mainly TA6/TA6, and the three genotype distributions of UGT1A1*28 were not related to gender, age stratification and regional differences in Chinese Han colorectal cancer patients.

参考文献/References:

[1]　WANG Zhengxu , CAO Junxia , LIU Zhiping, et al. Combination of chemotherapy and immunotherapy for colon cancer in China: A metaanalysis[ J]. World Journal of Gastroenterology, 2014, 20(4):1095-1106.
[2]　DOUILLARD J Y, CUNNINGHAM D, ROTH A D, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. The Lancet, 2000, 355(9209): 1041- 1047.
[3]　赵荣荣, 牛作兴. UGT1A1*28 基因多态性与伊立替 康疗效和毒副作用相关性研究进展[J]. 中华肿瘤防 治杂志, 2013, 20(9): 717-720. ZHAO Rongrong, NIU Zuoxing. Association of UGT1A1* 28 polymorphism with the efficacy and toxicity of irinotecan chemotherapy [J]. Chinese J Cancer Prev Treat, 2013, 20(9): 717-720.
[4]　OHNO S , NAKAJIN S . Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction[J]. Drug Metab Dispos, 2009, 37(1):32-40.
[5]　张君孝, 王晨亮, 黄美近, 等. UGT1A1 基因多态性 与转移性结直肠癌伊立替康化疗毒性及疗效的关系 [J]. 中国病理生理杂志, 2012, 28(5): 823-828. ZHANG Junxiao, WANG Chenliang, HUANG Meijin, et al. Relationship between UGT1A1 gene polymorphisms and toxicity/efficacy of irinotecan-based chemotherapy in metastatic colorectal cancer[J]. Chinese Journal of Pathophysiology, 2012, 28(5): 823- 828.
[6]　LIU Xinghua, LU Jun, DUAN Wei, et al. Predictive value of UGT1A1*28 polymorphism in irinotecanbased chemotherapy[J]. Journal of Cancer, 2017, 8(4): 691-703.
[7]　RIERA P, SALAZAR J, VIRGILI A C, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity[J]. British Journal of Clinical Pharmacology, 2018, 84(6): 1389- 1392.
[8]　SIEGEL R L，MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA: A Cancer Journal for Clinicians, 2017, 67(1):7-30.
[9]　CHEN Wanqing , ZHENG Rongshou, BAADE P D , et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
[10] 吴泽华, 邓艳红. 结直肠癌流行病学东西方差异对 肿瘤部位的影响[J]. 中国癌症防治杂志, 2017, 9(5): 356-360. WU Zehua, DENG Yanhong. Effect of epidemiological differences between east and west on tumor location in colorectal cance[J]. Chinese Journal of Oncology Prevention and Treatment, 2017, 9(5): 356-360.
[11] LI Guoyin, DUAN Jianfeng, LI Wanjun, et al. DPYD* 2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients[J]. Journal of Cancer Research and Therapeutics, 2016, 12(2): 782-786.
[12] 黄春锦, 张 浩. 282 例结直肠癌患者 UGT1A1* 28 基 因多态性分析[J]. 国际检验医学杂志, 2015, 36(9): 1173-1175. HUANG Chunjin, ZHANG Hao. Analysis on gene polymorphism of UGT1A1*28 in 282 cases of colorectal cancer[J]. International Journal of Laboratory Medicine, 2015, 36(9): 1173-1175.
[13] 孙 建, 姜 婷, 田 宇, 等. 维吾尔族结肠癌患者 UGT1A1 基因多态性与伊立替康毒性的相关性[J]. 中国 医学创新, 2017, 14(20): 65-68. SUN Jian, JIANG Ting, TIAN Yu, et al. Correlation of UGT1A1 gene polymorphism and irinotecan toxicity in uygur colorectal carcinoma patients[J]. Medical Innovation of China, 2017, 14(20): 65-68.
[14] ATASILP C, CHANSRIWONG P, SIRACHAINAN E, et al. Correlation of UGT1A1* 28 and* 6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients[J]. Drug Metabolism and Pharmacokinetics, 2016, 31(1): 90-94.
[15] ALKHARFY K M, ALGHAMDI A M, BAGULB K M, et al. Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population[J]. Archives of Medical Science, 2013, 9(4): 731-738.
[16] MARSH S, KING C R, VAN BOOVEN D J, et al. Pharmacogenomic assessment of Mexican and Peruvian populations[J]. Pharmacogenomics, 2015, 16(5): 441- 448.

相似文献/References:

[1]陈建国.结直肠癌患者FOLFOX化疗与GSTP1,XRCC1基因多态性的研究[J].现代检验医学杂志,2016,31(05):66.[doi:10.3969/j.issn.1671-7414.2016.05.017]
　CHEN Jian-guo.Relationship between FOLFOX Chemotherapy of Colorectal Cancer Patients and GSTP1,XRCC1 Gene Polymorphism[J].Journal of Modern Laboratory Medicine,2016,31(06):66.[doi:10.3969/j.issn.1671-7414.2016.05.017]
[2]周秋媛,王红莉,李虹,等.NRP-1和NRP-2在结直肠癌组织中的表达水平及临床意义[J].现代检验医学杂志,2016,31(06):85.[doi:10.3969/j.issn.1671-7414.2016.06.024]
　ZHOU Qiu-yuan,WANG Hong-li,LI Hong,et al.Serum NRP-1 and NRP-2 Expression in Colorectal Cancer Patients and Its Relationship with Clinical Pathology[J].Journal of Modern Laboratory Medicine,2016,31(06):85.[doi:10.3969/j.issn.1671-7414.2016.06.024]
[3]史 敏,郭晓波,李思远,等.结直肠癌患者组织中K-ras和BRAF基因突变与不同病理特征的相关性分析[J].现代检验医学杂志,2018,33(03):27.[doi:10.3969/j.issn.1671-7414.2018.03.009]
　SHI Min,GUO Xiao-bo,LI Si-yuan,et al.Correlation of K-ras and BRAF Mutations with Pathological Features in Patients with Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):27.[doi:10.3969/j.issn.1671-7414.2018.03.009]
[4]井丰军,倪勇.结直肠癌患者外周血NLR与RDW的变化及临床意义[J].现代检验医学杂志,2018,33(03):99.[doi:10.3969/j.issn.1671-7414.2018.03.025]
　JING Feng-jun,NI Yong.Change and Significance of Neutrophil/Lymphocyte Ratio and Red Blood Cell Distribution Width of Peripheral Blood in the Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):99.[doi:10.3969/j.issn.1671-7414.2018.03.025]
[5]陈 培,邓钦木,李丹丹.血浆Septin9 甲基化检测在结直肠癌中的诊断价值[J].现代检验医学杂志,2020,35(04):10.[doi:10.3969/j.issn.1671-7414.2020.04.003]
　CHEN Pei,DENG Qin-mu,LI Dan-dan.Diagnostic Value of Plasma Septin9 Methylation in Screening of Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):10.[doi:10.3969/j.issn.1671-7414.2020.04.003]
[6]杨婕琳a,陈文婷b,胡晓利a.结直肠癌组织中硫氧还蛋白-1与硫氧还蛋白互作蛋白的表达及其临床意义[J].现代检验医学杂志,2021,36(06):22.[doi:10.3969/j.issn.1671-7414.2021.06.005]
　YANG Jie-lin,CHEN Wen-ting,HU Xiao-li.Expression and Clinical Significance of Thioredoxin-1 and Thioredoxin Interacting Protein in Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):22.[doi:10.3969/j.issn.1671-7414.2021.06.005]
[7]马胜辉,崔雪琴,李建华,等.结直肠癌组织miR-485-5p，miR-1207-3p和miR-590-3p水平表达与临床病理特征及生存的相关性研究[J].现代检验医学杂志,2022,37(03):16.[doi:10.3969/j.issn.1671-7414.2022.03.004]
　MA Sheng-hui,CUI Xue-qin,LI Jian-hua,et al.Correlation of miR-485-5p, miR-1207-3p, miR-590-3p Level Expression and Clinicopathologic Characteristics and Survival in Colorectal Cancer Tissue[J].Journal of Modern Laboratory Medicine,2022,37(06):16.[doi:10.3969/j.issn.1671-7414.2022.03.004]
[8]胡道军,史文杰,孙 敏.LncRNA NEAT1/miR-23b-3p/KLF3 轴调控结直肠癌细胞的生物学功能研究[J].现代检验医学杂志,2022,37(04):1.[doi:10.3969/j.issn.1671-7414.2022.04.001]
　HU Dao-jun,SHI Wen-jie,SUN Min.LncRNA NEAT1/miR-23b-3p/ KLF3 Axis Regulates the Biological Function of Colorectal Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(06):1.[doi:10.3969/j.issn.1671-7414.2022.04.001]
[9]冯 芬.结直肠癌组织中USP11 和PPP1CA 表达水平与临床病理的相关性研究[J].现代检验医学杂志,2022,37(04):43.[doi:10.3969/j.issn.1671-7414.2022.04.009]
　FENG Fen.Correlation between USP11 and PPP1CA Expression Levels and Clinicopathology in Colorectal Cancer Tissues[J].Journal of Modern Laboratory Medicine,2022,37(06):43.[doi:10.3969/j.issn.1671-7414.2022.04.009]
[10]郑光明,孙建华,宋秋月.结直肠癌组织中锌指蛋白139（ZNF139）的表达及临床意义研究[J].现代检验医学杂志,2022,37(04):107.[doi:10.3969/j.issn.1671-7414.2022.04.021]
　ZHENG Guang-ming,SUN Jian-hua,SONG Qiu-yue.Expression and Clinical Significance of Zinc Finger Protein 139 (ZNF139) in Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2022,37(06):107.[doi:10.3969/j.issn.1671-7414.2022.04.021]

备注/Memo

备注/Memo:
作者简介：滕祥云(1980-)，男，博士，研发总监，主要从事精准医学基因检测方面的研究，E-mail：1339035044@qq.com。 通信作者：李琦，男，硕士，经理，主要从事医学信息分析工作，E-mail：liqi@3gbio.com.cn。收稿日期：2019-09-03
更新日期/Last Update: 2019-12-25